Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Why Black Men’s Prostate Cancer May be More Responsive to Immunotherapy
Disease Discoveries

Why Black Men’s Prostate Cancer May be More Responsive to Immunotherapy

By Marla PaulFeb 10, 2021
Share
Facebook Twitter Email

Discovery paves way to precision medicine for prostate cancer in all races

Edward Schaeffer, MD, chair and the Edmund Andrews Professor of Urology and a Northwestern Medicine urologist, was the senior author of the study.

Black men die more often of prostate cancer yet, paradoxically, have greater survival benefits from immunotherapy treatment. A new Northwestern Medicine study has discovered the reason appears to be an increase of a surprising type of immune cell in the tumor. The findings, published in Nature Communications, could lead to immune-based precision medicine treatment for men of all races with localized aggressive and advanced prostate cancer.

In the new study, Northwestern scientists showed tumors from Black men and men of African ancestry have an increased proportion of a special immune cell called plasma cells compared to the tumors of white men. A research team lead by Edward Schaeffer, MD, chair and the Edmund Andrews Professor of Urology and a Northwestern Medicine urologist, found this increase in plasma cells correlated with improved cancer survival following surgery and identified plasma cells as potential drivers of prostate cancer immune-responsiveness.

“If a man’s prostate cancer has numerous plasma cells, we found he had improved cancer survival,” said Schaeffer, who is also program director of the Genitourinary Oncology Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. “Our study suggests plasma cells are important in the body’s response to cancer.”

Although recent research suggests Black men with advanced prostate cancer have improved survival outcomes with immunotherapy, there has been no way to predict which individual patients — Black or white — with prostate cancer may respond best to immunotherapy drugs.

Schaeffer’s team explored this by analyzing the genomics of 1,300 tumor samples annotated with self-identified race or genetic ancestry. They found, on average, more plasma cells in Black men’s tumors than white men’s.

The finding was not unique to Black men, and the work showed that in all men with elevated plasma cell levels there was improved cancer-free survival following surgery.

“The finding comes at a time as researchers are discovering plasma cells may play a greater role in cancer immunotherapy than previously thought,” said first author Adam Weiner, MD, a Northwestern Medicine urology resident. “Testing for plasma cells in prostate cancer may help identify men who will benefit from immune-based treatments.”

Schaeffer’s research team at the Polsky Urologic Cancer Institute of the Lurie Cancer Center is now developing immunotherapy-based precision medicine clinical trials to investigate whether increased levels of plasma cells in prostate cancers from men of all races and ancestry can enhance the efficacy of immunotherapy and improved survival.

Prostate cancer is the second most common cancer in American men with an estimated 175,000 new cases every year and about 32,000 deaths. The severity and resulting mortality from prostate cancer are about two times greater in patients of African American origin. Identification and characterization of effective therapeutic targets is a significant and unmet need to improve clinical outcomes and reduce mortality from lethal prostate cancer among African American men.

The research was supported by the Polsky Urologic Cancer Institute, grant 5U01CA196390 from National Cancer Institute of the National Institutes of Health, the Prostate Cancer Foundation, the 2019 Urology Care Foundation Residency Research Award Program and the Russell Scott, Jr., MD Urology Research Fund.

Cancer Press Release Public Health Research
Share. Facebook Twitter Email

Related Posts

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Comments are closed.

Latest News

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Student Spearheads Ukraine Aid Efforts

Jun 27, 2022

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20220617_NM_0434
20220617_NM_0858
20220617_NM_0643
20220617_NM_0835
20220617_NM_0544
20220617_NM_0450
20220617_NM_0790
20220617_NM_0811
20220617_NM_0851
20220617_NM_0696
20220617_NM_0779
20220617_NM_0838

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.